Methylglyoxal increases cardiomyocyte ischemia-reperfusion injury via glycative inhibition of thioredoxin activity.
Diabetes mellitus (DM) is closely related to cardiovascular morbidity and mortality, but the specific molecular basis linking DM with increased vulnerability to cardiovascular injury remains incompletely understood. Methylglyoxal (MG), a precursor to advanced glycation end products (AGEs), is increased in diabetic patient plasma, but its role in diabetic cardiovascular complications is unclear. Thioredoxin (Trx), a cytoprotective molecule with antiapoptotic function, has been demonstrated to be vulnerable to glycative inhibition, but whether Trx is glycatively inhibited by MG, thus contributing to increased cardiac injury, has never been investigated. Cultured H9c2 cardiomyocytes were treated with MG (200 muM) for 6 days. The following were determined pre- and post-simulated ischemia-reperfusion (SI-R; 8 h of hypoxia followed by 3 h of reoxygenation): cardiomyocyte death/apoptosis, Trx expression and activity, AGE formation, Trx-apoptosis-regulating kinase-1 (Trx-ASK1) complex formation, and p38 mitogen-activated protein kinase (MAPK) phosphorylation and activity. Compared with vehicle, MG significantly increased SI-R-induced cardiomyocyte LDH release and apoptosis (P < 0.01). Prior to SI-R, Trx activity was reduced in MG-treated cells, but Trx expression was increased moderately. Moreover, Trx-ASK1 complex formation was reduced, and both p38 MAPK activity and phosphorylation were increased. To investigate the effects of MG on Trx directly, recombinant human Trx (hTrx) was incubated with MG in vitro. Compared with vehicle, MG incubation markedly increased CML formation (a glycation footprint) and inhibited Trx activity. Finally, glycation inhibitor aminoguanidine administration during MG treatment of cultured cells reduced AGE formation, increased Trx activity, restored Trx-ASK1 interaction, and reduced p38 MAPK phosphorylation and activity, caspase-3 activation, and LDH release (P < 0.01). We demonstrated for the first time that methylglyoxal sensitized cultured cardiomyocytes to SI-R injury by posttranslational modification of Trx via glycation. Therapeutic interventions scavenging AGE precursors may attenuate ischemic-reperfusion injury in hyperglycemic state diseases such as diabetes.
Wang
Xiao-Liang
XL
Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Lau
Wayne B
WB
Yuan
Yue-Xing
YX
Wang
Ya-Jing
YJ
Yi
Wei
W
Christopher
Theodore A
TA
Lopez
Bernard L
BL
Liu
Hui-Rong
HR
Ma
Xin-Liang
XL
D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D015153:Blotting, Western; D002478:Cells, Cultured; D017127:Glycation End Products, Advanced / Q000378:metabolism*; D007150:Immunohistochemistry; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D015428:Myocardial Reperfusion Injury / Q000473:pathology*; D032383:Myocytes, Cardiac / Q000473:pathology*; D011765:Pyruvaldehyde / Q000494:pharmacology*; D051381:Rats; D011994:Recombinant Proteins / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction / Q000502:physiology; D013879:Thioredoxins / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000235:genetics; D048051:p38 Mitogen-Activated Protein Kinases / Q000378:metabolism
D017127:Glycation End Products, Advanced; D011994:Recombinant Proteins; C495697:Txn1 protein, rat; D013879:Thioredoxins; D011765:Pyruvaldehyde; D007770:L-Lactate Dehydrogenase; D048051:p38 Mitogen-Activated Protein Kinases
Kidney Int. 2003 Mar;63(3):947-57
12631075
Methods Enzymol. 1995;252:199-208
7476354
J Cell Mol Med. 2009 Aug;13(8B):1751-1764
19602045
N Engl J Med. 1986 Feb 13;314(7):403-8
3945267
Diabetes. 2005 Nov;54(11):3274-81
16249455
Proc Natl Acad Sci U S A. 2004 Aug 3;101(31):11471-6
15277664
FASEB J. 2006 Jul;20(9):1555-7
16723378
Mol Cell Biochem. 1998 Apr;181(1-2):63-9
9562242
Electrophoresis. 2007 Nov;28(21):3940-7
17924366
Toxicology. 2010 Jan 31;268(1-2):89-97
20004697
Free Radic Biol Med. 2010 Aug 1;49(3):332-8
20416371
Diabetes Obes Metab. 2007 May;9(3):233-45
17391149
Nat Cell Biol. 2002 Oct;4(10):743-9
12244325
Diabetes. 1994 Jun;43(6):836-41
8194672
Free Radic Biol Med. 2000 Aug;29(3-4):312-22
11035260
Metabolism. 2006 Feb;55(2):232-6
16423631
Rejuvenation Res. 2006 Summer;9(2):274-8
16706655
FASEB J. 2006 Feb;20(2):259-68
16449798
EMBO J. 1998 May 1;17(9):2596-606
9564042
Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):9745-9
12119401
J Clin Invest. 1994 Feb;93(2):759-67
8113409
Clin Biochem. 2005 Feb;38(2):103-15
15642271
J Cell Biochem. 2000 Mar;77(2):333-44
10723098
Mol Cell Biochem. 2007 Jul;301(1-2):251-7
17549609
Biochem Biophys Res Commun. 1999 Mar 5;256(1):89-93
10066428
Antioxid Redox Signal. 2004 Apr;6(2):405-12
15025942
Cardiovasc Res. 2002 Feb 1;53(2):414-22
11827692
Anticancer Res. 2003 May-Jun;23(3B):2425-33
12894524
Circ Res. 2002 Jun 28;90(12):1259-66
12089063
Antioxid Redox Signal. 2004 Feb;6(1):15-7
14713332
Life Sci. 2007 Feb 20;80(11):1051-6
17174344
Free Radic Biol Med. 2001 Jul 1;31(1):20-30
11425486
Free Radic Biol Med. 2000 Feb 1;28(3):418-27
10699754
Proc Natl Acad Sci U S A. 1998 May 12;95(10):5533-8
9576917
J Immunol Methods. 1983 Nov 25;64(3):313-20
6199426
Mol Cells. 2003 Apr 30;15(2):194-9
12803482
Curr Cardiol Rep. 2003 Sep;5(5):337
12917044
Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4630-4
9539789
Amino Acids. 2003 Dec;25(3-4):275-81
14661090
J Biol Chem. 2005 Apr 1;280(13):12310-5
15677467
Circulation. 2004 Aug 17;110(7):856-61
15289372
J Biol Chem. 1997 Jul 18;272(29):18453-9
9218489
J Biol Chem. 2004 Mar 5;279(10):8820-6
14681238
Antioxid Redox Signal. 2003 Oct;5(5):563-70
14580311
Ann N Y Acad Sci. 2005 Jun;1043:151-7
16037234
Am J Physiol Cell Physiol. 2008 Dec;295(6):C1510-7
18842828
J Pharmacol Toxicol Methods. 2005 Mar-Apr;51(2):153-7
15767209